Literature DB >> 12069988

Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis.

Montserrat Ortoneda1, Javier Capilla, Francisco J Pastor, Isabel Pujol, Josep Guarro.   

Abstract

We have compared the activities of liposomal amphotericin B (LAMB) at 3, 5, 10, and 20 mg/kg/day and amphotericin B deoxycholate (AMB) at 1.5 and 2.5 mg/kg/day in a murine systemic infection by Fusarium verticillioides. Survival was improved by all treatments except AMB at 1.5 mg/kg/day. The tissue burden in liver was reduced by LAMB at all dosages and by AMB at 2.5 mg/kg/day. The two highest dosages of LAMB showed significant reductions in the spleen.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12069988      PMCID： PMC127282          DOI： 10.1128/AAC.46.7.2273-2275.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Treatment of systemic fungal infections with liposomal amphotericin B.

Authors:  G Lopez-Berestein; G P Bodey; V Fainstein; M Keating; L S Frankel; B Zeluff; L Gentry; K Mehta
Journal:  Arch Intern Med       Date:  1989-11

Review 2.  Disseminated infection with Fusarium in recipients of bone marrow transplants.

Authors:  A S Gamis; T Gudnason; G S Giebink; N K Ramsay
Journal:  Rev Infect Dis       Date:  1991 Nov-Dec

3.  Lack of activity of amphotericin B in systemic murine fusarial infection.

Authors:  E J Anaissie; R Hachem; C Legrand; P Legenne; P Nelson; G P Bodey
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

Review 4.  Disseminated fusarial infection in the immunocompromised host.

Authors:  S E Richardson; R M Bannatyne; R C Summerbell; J Milliken; R Gold; S S Weitzman
Journal:  Rev Infect Dis       Date:  1988 Nov-Dec

5.  In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole.

Authors:  R K Li; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

6.  Infection with Fusarium species in two children with neuroblastoma.

Authors:  C Viscoli; E Castagnola; C Moroni; A Garaventa; G Manno; C Savioli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

7.  Disseminated infection by Fusarium moniliforme during treatment for malignant lymphoma.

Authors:  N A Young; K J Kwon-Chung; T T Kubota; A E Jennings; R I Fisher
Journal:  J Clin Microbiol       Date:  1978-06       Impact factor: 5.948

8.  Efficacy of liposomal amphotericin B (AmBisome) in the eradication of Fusarium infection in a leukaemic patient.

Authors:  E Cofrancesco; C Boschetti; M A Viviani; C Bargiggia; A M Tortorano; M Cortellaro; C Zanussi
Journal:  Haematologica       Date:  1992 May-Jun       Impact factor: 9.941

9.  Fusarium as a pathogen. A case report of Fusarium sepsis and review of the literature.

Authors:  K S Veglia; V J Marks
Journal:  J Am Acad Dermatol       Date:  1987-01       Impact factor: 11.527

Review 10.  Fusarium infections in immunocompromised patients: case reports and literature review.

Authors:  M Rabodonirina; M A Piens; M F Monier; E Guého; D Fière; M Mojon
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-02       Impact factor: 3.267
View more
  12 in total

1.  Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex.

Authors:  Mónica Azor; Josepa Gené; Josep Cano; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.

Authors:  Jon A Olson; Jill P Adler-Moore; Gerard M Jensen; Julie Schwartz; M Cecilia Dignani; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

3.  Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.

Authors:  Jon A Olson; Jill P Adler-Moore; P J Smith; Richard T Proffitt
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 4.  Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.

Authors:  João F Lacerda; Carlos Meneses Oliveira
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

5.  Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata.

Authors:  Marçal Mariné; Carolina Serena; Belkys Fernández-Torres; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 6.  The challenge of managing fusariosis.

Authors:  Maged Muhammed; Jeffrey J Coleman; Herman A Carneiro; Eleftherios Mylonakis
Journal:  Virulence       Date:  2011-03-01       Impact factor: 5.882

Review 7.  Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.

Authors:  Marit D Moen; Katherine A Lyseng-Williamson; Lesley J Scott
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Efficacy of triazoles in a murine disseminated infection by Candida krusei.

Authors:  Marçal Mariné; F Javier Pastor; Carolina Serena; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

Review 9.  Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment.

Authors:  J Guarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-11       Impact factor: 3.267

10.  Activity of Amphotericin B Formulations and Voriconazole, Alone or in Combination, against Biofilms of Scedosporium and Fusarium spp.

Authors:  Katerina Vikelouda; Maria Simitsopoulou; Lemonia Skoura; Charalampos Antachopoulos; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.